How many insider trades does FilingIQ track for GLUE?

FilingIQ tracks 120 Form 4 insider transactions for GLUE (Monte Rosa Therapeutics, Inc.), covering filings from Jun 28, 2021 onwards. 14 of those were filed in the last 90 days.

Are GLUE insiders net buyers or net sellers?

Across the full Form 4 history for GLUE, 17 transactions (14%) were open-market purchases and 27 (23%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does GLUE insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is GLUE in?

Monte Rosa Therapeutics, Inc. (GLUE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.46B.

GLUE insider trading

NasdaqGS Healthcare

Monte Rosa Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

120

Last 90 days

Buys / sells

14% / 23%

Market cap

$1.46B

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Company website: www.monterosatx.com

GLUE insider activity at a glance

FilingIQ has scored 120 insider transactions for GLUE since Jun 28, 2021. The most recent filing in our index is dated May 1, 2026.

Across the full history, 17 open-market purchases and 27 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on GLUE insider trades is 54.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live GLUE trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for GLUE?: FilingIQ tracks 120 Form 4 insider transactions for GLUE (Monte Rosa Therapeutics, Inc.), covering filings from Jun 28, 2021 onwards. 14 of those were filed in the last 90 days.
Are GLUE insiders net buyers or net sellers?: Across the full Form 4 history for GLUE, 17 transactions (14%) were open-market purchases and 27 (23%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does GLUE insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is GLUE in?: Monte Rosa Therapeutics, Inc. (GLUE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.46B.

Methodology & sources

Every GLUE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.